Publication: Comment on: F.M. Scherer, "How US antitrust can go astray: the brand name prescription drug litigation"
Comment on: F.M. Scherer, "How US antitrust can go astray: the brand name prescription drug litigation"
Date
Date
Date
Citations
Zweifel, P. (1997). Comment on: F.M. Scherer, “How US antitrust can go astray: the brand name prescription drug litigation.” International Journal of the Economics of Business, 4(3), 277–279. https://doi.org/10.1080/758523209
Abstract
Abstract
Abstract
Comments on the article `How US Antirust Can Go Astray: The Brand Name Prescription Drug Litigation,' by F.M. Scherer. Discussion of the issue of patent protection; Uniform monopoly price; Summary of price differentiation between groups of consumers.
Metrics
Citations
Additional indexing
Creators (Authors)
- Zweifel, Peter
Journal/Series Title
Journal/Series Title
Journal/Series Title
Volume
Volume
Volume
Number
Number
Number
Page Range
Page Range
Page Range
Page end
Page end
Page end
Item Type
Item Type
Item Type
In collections
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Other Identification Number
Other Identification Number
Other Identification Number
Related URLs
Related URLs
Related URLs
Metrics
Citations
Citations
Zweifel, P. (1997). Comment on: F.M. Scherer, “How US antitrust can go astray: the brand name prescription drug litigation.” International Journal of the Economics of Business, 4(3), 277–279. https://doi.org/10.1080/758523209
